Recent Submissions

  • Extracellular proteases regulate adipose derived bioactive chemerin 

    Parlee, S. D., and K. B. Goralski. 2010. "Extracellular proteases regulate adipose derived bioactive chemerin." Journal of Population Therapeutics and Clinical Pharmacology 17(1): 205-e206.
    Background: Chemerin, a hormone-like protein, affects cell differentiation, metabolism and inflammation. It is released from cells as inactive prochemerin and is converted to active chemerin by extracellular proteases. ...
  • Identification of adipose-derived proteases involved in the regulation of chemerin function 

    Parlee, S. D., and K. B. Goralski. 2011. "Identification of adipose-derived proteases involved in the regulation of chemerin function." Obesity Reviews 12: 164.
    Introduction: Chemerin, an adipokine is positively associated with obesity and implicated in adipogenesis and inflammation via chemokine like receptor-1 (CMKLR1) signaling. Chemerin is secreted as inactive prochemerin and ...
  • TNF(alpha) enhances the expression and secretion of chemerin from adipocytes 

    Parlee, S. D., M. C. Ernst, C. J. Sinal, and K. B. Goralski. 2009. "TNF(alpha) enhances the expression and secretion of chemerin from adipocytes." The FASEB Journal 23(S1).
    We recently identified a novel adipokine, chemerin that regulates adipogenesis and adipose metabolism via the chemokine-like receptor 1 (CMKLR1). In humans, serum chemerin levels modestly correlate with measures of body ...
  • Evaluation of oral dabigatran etexilate pharmacokinetics and pharmacodynamics in hemodialysis patients 

    Wilson, J. -A, K. B. Goralski, S. D. Soroka, D. R. Anderson, et al. 2013. "Evaluation of oral dabigatran etexilate pharmacokinetics and pharmacodynamics in hemodialysis patients." American Journal of Kidney Diseases 61(4): 99.
    Purpose of the Study: Dabigatran etexilate represents a possible improved alternative to warfarin for anticoagulation in hemodialysis patients with atrial fibrillation (AF). The object was to determine dabigatran plasma ...
  • Chemerin exacerbates glucose intolerance in mouse models of obesity and diabetes 

    Ernst, M. C., M. Issa, K. B. Goralski, and C. J. Sinal. 2010. "Chemerin exacerbates glucose intolerance in mouse models of obesity and diabetes." Endocrinology 151(5): 1998-2007.
    Obesity, characterized by an excess of adipose tissue, is an established risk factor for cardiovascular disease and type 2 diabetes. Different mechanisms linking obesity with these comorbidities have been postulated but ...
  • Chapter 14 Elucidation of Chemerin and Chemokine-Like Receptor-1 Function in Adipocytes by Adenoviral-Mediated shRNA Knockdown of Gene Expression 

    Goralski, K. B., and C. J. Sinal. 2009. "Chapter 14 Elucidation of Chemerin and Chemokine-Like Receptor-1 Function in Adipocytes by Adenoviral-Mediated shRNA Knockdown of Gene Expression." Methods in Enzymology 460(A): 289-312.
  • Toll-like receptor-4 regulation of hepatic Cyp3a11 metabolism in a mouse model of LPS-induced CNS inflammation 

    Goralski, K. B., D. Abdulla, C. J. Sinal, A. Arsenault, et al. 2005. "Toll-like receptor-4 regulation of hepatic Cyp3a11 metabolism in a mouse model of LPS-induced CNS inflammation." American Journal of Physiology - Gastrointestinal and Liver Physiology 289(3 52-3): 434443-G434; G443.
    Central nervous system (CNS) infection and inflammation severely reduce the capacity of cytochrome P-450 metabolism in the liver. We developed a mouse model to examine the effects of CNS inflammation on hepatic cytochrome ...
  • Chemerin, a novel Peroxisome Proliferator-activated Receptor (gamma) (PPAR(gamma)) target gene that promotes mesenchymal stem cell adipogenesis 

    Muruganandan, S., S. D. Parlee, J. L. Rourke, M. C. Ernst, et al. 2011. "Chemerin, a novel Peroxisome Proliferator-activated Receptor (gamma) (PPAR(gamma)) target gene that promotes mesenchymal stem cell adipogenesis." Journal of Biological Chemistry 286(27): 23982-23995.
    Chemerin is an adipocyte-secreted protein that regulates adipogenesis and the metabolic function of mature adipocytes via activation of chemokine-like receptor 1 (CMKLR1). Herein we report the interaction of peroxisome ...
  • Serum chemerin levels vary with time of day and are modified by obesity and tumor necrosis factor-(alpha) 

    Parlee, S. D., M. C. Ernst, S. Muruganandan, C. J. Sinal, et al. 2010. "Serum chemerin levels vary with time of day and are modified by obesity and tumor necrosis factor-(alpha)." Endocrinology 151(6): 2590-2602.
    Chemerin is an adipokine with important regulatory roles in adipogenesis. In humans, serum total chemerin (i.e. prochemerin plus chemerin) levels are positively associated withbodymass indexand metabolic syndrome. However, ...
  • Jadomycins Derived from the Assimilation and Incorporation of Norvaline and Norleucine 

    Dupuis, Stephanie N., Thomas Veinot, Susan M. A. Monro, Susan E. Douglas, et al. 2011. "Jadomycins Derived from the Assimilation and Incorporation of Norvaline and Norleucine." Journal of natural products 74(11): 2420-2424.
    Streptomyces venezuelae ISP5230 is recognized for the production of chloramphenicol and the jadomycin family of natural products. The jadomycins are angucycline natural products containing a unique oxazolone ring incorporating ...
  • Investigation of the cytotoxcity of novel jadomycins in drug resistant breast cancer cells 

    Goralski, K. B., C. L. Graham, M. Issa, and D. L. Jakeman. 2009. "Investigation of the cytotoxcity of novel jadomycins in drug resistant breast cancer cells." The FASEB Journal 23(S1).
    The drug transporter ABCB1 plays a major role in drug resistance and chemotherapy failure in the treatment of breast cancer. Jadomycins are natural products synthesized by the bacteria S. venezuelae ISP5230 and inhibit the ...
  • Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism 

    Goralski, K. B., T. C. McCarthy, E. A. Hanniman, B. A. Zabel, et al. 2007. "Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism." Journal of Biological Chemistry 282(38): 28175-28188.
    Obesity is an alarming primary health problem and is an independent risk factor for type II diabetes, cardiovascular diseases, and hypertension. Although the pathologic mechanisms linking obesity with these co-morbidities ...
  • Evaluation of oral dabigatran etexilate pharmacokinetics and pharmacodynamics in hemodialysis patients 

    Goralski, K., M. Morrison, P. Mossop, S. Soroka, et al. 2013. "Evaluation of oral dabigatran etexilate pharmacokinetics and pharmacodynamics in hemodialysis patients." FASEB Journal 27.
    Background: Dabigatran etexilate represents a possible improved alternative to warfarin for anticoagulation in hemodialysis patients with atrial fibrillation (AF). The object was to determine dabigatran plasma concentrations ...
  • Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function 

    Seubert, J. M., C. J. Sinal, J. Graves, L. M. Degraff, et al. 2006. "Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function." Circulation research 99(4): 442-450.
    Cytochrome P450 epoxygenases metabolize arachidonic acid to epoxyeicosatrienoic acids (EETs) which are converted to dihydroxyeicosatrienoic acids (DHETs) by soluble epoxide hydrolase (Ephx2, sEH). To examine the functional ...
  • Oseltamivir pharmacokinetics in morbid obesity (OPTIMO trial) 

    Thorne-Humphrey, L. M., K. B. Goralski, K. L. Slayter, T. F. Hatchette, et al. 2011. "Oseltamivir pharmacokinetics in morbid obesity (OPTIMO trial)." Journal of Antimicrobial Chemotherapy 66(9): 2083-2091.
    Background: Detailed pharmacokinetics to guide oseltamivir (Tamiflu (R)) dosing in morbidly obese patients is lacking. Methods: The OPTIMO trial was a single-centre, non-randomized, open-label pharmacokinetic study of ...
  • Oseltamivir pharmacokinetics in morbid obesity (OPTIMO trial) 

    Thorne-Humphrey, L., K. Slayter, K. Goralski, T. Hatchette, et al. 2010. "Oseltamivir pharmacokinetics in morbid obesity (OPTIMO trial)." Canadian Journal of Infectious Diseases and Medical Microbiology 21: 39-40A.
    OBjEcTivES: Morbid obesity exceeds 2.7% of the adult Canadian population. Some drugs require dose adjustment in obesity but for many drugs, detailed pharmacokinetics to guide drug dosing for the morbidly obese patient is ...
  • A critical overview of the influence of inflammation and infection on P-glycoprotein expression and activity in the brain 

    Roberts, Derek J., and Kerry B. Goralski. 2008. "A critical overview of the influence of inflammation and infection on P-glycoprotein expression and activity in the brain." Expert Opinion on Drug Metabolism & Toxicology 4(10): 1245-1264.
    Background: P-glycoprotein is a blood-brain barrier efflux transporter that limits drug accumulation in the brain. Objective: To review recent in vivo and in vitro investigations that examined the influence of inflammation, ...
  • Surgery-induced inflammation reduces morphine distribution into cerebrospinal fluid 

    Wang, Y., K. Landry, M. Issa, L. Sleno, et al. 2013. "Surgery-induced inflammation reduces morphine distribution into cerebrospinal fluid." FASEB Journal 27.
    Objective: To determine the effects of surgery-induced inflammation on morphine distribution across blood-brain barrier (BBB) Methods: Blood and cerebrospinal fluid (CSF) concentrations of morphine were measured in adult ...
  • Elastase and Tryptase Govern TNF alpha-Mediated Production of Active Chemerin by Adipocytes 

    Parlee, Sebastian D., Jenna O. McNeil, Shanmugam Muruganandan, Christopher J. Sinal, et al. 2012. "Elastase and Tryptase Govern TNF alpha-Mediated Production of Active Chemerin by Adipocytes." Plos One 7(12): 51072-e51072.
    Chemerin is a leukocyte chemoattractant and adipokine with important immune and metabolic roles. Chemerin, secreted in an inactive form prochemerin, undergoes C-terminal proteolytic cleavage to generate active chemerin, a ...
  • Paradoxical cyclosporine A requirements in pediatric renal transplants receiving high-dose steroids 

    Hardy, KW, JFS Crocker, H. McLellan, KB Goralski, et al. 2005. "Paradoxical cyclosporine A requirements in pediatric renal transplants receiving high-dose steroids." Journal of clinical pharmacology 45(2): 161-167.
    The potent immunosuppressant cyclosporine A (CyA) is a mainstay of treatment in the renal transplant population. During episodes of acute allograft rejection, therapy also includes the pulse administration of high-dose ...

View more